UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Finance receivable interest income, including fees	$ 8,502	$ 9,373	$ 25,745	$ 29,857
Pharmaceutical development	5,111	187	5,461	10,846
Other	1		481	496
Total revenues	13,614	9,560	31,687	41,199
Costs and expenses:
Interest expense	82	53	242	292
Pharmaceutical manufacturing, research and development expense	1,792	2,487	5,173	5,577
Change in fair value of acquisition-related contingent consideration				(147)
Depreciation and amortization expense	634	812	1,964	3,305
General and administrative	4,349	3,580	10,527	9,825
Income from operations	6,757	2,628	13,781	22,347
Other income (expense), net
Unrealized net gain (loss) on derivatives	1,788	(214)	623	678
Unrealized net gain (loss) on equity securities	13	342	(534)	1,557
Income before income tax expense	8,558	2,756	13,870	24,582
Income tax expense	1,942	513	3,211	4,980
Net income	$ 6,616	$ 2,243	$ 10,659	$ 19,602
Net income per share
Basic	$ 0.52	$ 0.18	$ 0.83	$ 1.53
Diluted	$ 0.51	$ 0.17	$ 0.83	$ 1.53
Weighted average shares outstanding
Basic	12,832,000	12,798,000	12,832,000	12,796,000
Diluted	12,851,000	12,859,000	12,871,000	12,834,000